NCT05848466View on ClinicalTrials.gov

Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors Patients

PHASE1UnknownINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

February 10, 2023

Primary Completion Date

May 31, 2025

Study Completion Date

July 31, 2025

Conditions
Advanced or Metastatic Solid Tumors
Interventions
DRUG

BAT8010 for Injection

Intravenous

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

Sponsors
All Listed Sponsors
lead

Bio-Thera Solutions

INDUSTRY